(NASDAQ: ENGN) Engene Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Engene Holdings's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast ENGN's revenue for 2027 to be $1,907,376,385, with the lowest ENGN revenue forecast at $534,244,829, and the highest ENGN revenue forecast at $4,427,859,884. On average, 5 Wall Street analysts forecast ENGN's revenue for 2028 to be $6,020,347,881, with the lowest ENGN revenue forecast at $3,974,720,353, and the highest ENGN revenue forecast at $8,345,026,572.
In 2029, ENGN is forecast to generate $11,766,436,489 in revenue, with the lowest revenue forecast at $9,948,270,834 and the highest revenue forecast at $14,258,423,532.